芝加哥大学

乳腺癌精准诊疗

RDS®

First multi-gene expression profile to predict efficacy of DNA damaged therapies for ER negative breast cancer

  • Quantitative detection for DNA recombination repair defects
  • Independently predict the prognosis and efficacy of DNA damaged therapies
  • Original patent of Professor Connell, University of Chicago
  • Exclusive worldwide license

PRODUCT ADVANTAGES

  • Duplex one-step RT-qPCR reaction
  • Good amplification efficiency
  • Minimum detection limit (10 copies)
  • Convenient calculation formula
  • Cell line and clinical verified

DETECTION REQUIREMENTS

  • Suitable for surgery or puncture biopsy paraffin-embedded (FFPE) sections , 5μm/ 7 pieces
  • Suitable for a variety of PCR instruments (e.g. Light Cycler 480II, ABI 7500, Agilent Mx3000P, etc.)

文献参考